Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Robert J Lin, et al.
Older patients should not be excluded from CAR T based on chronologic age alone; these results highlight potential benefits of CAR T in selected older patients even with functional limitation, multi-morbidity, and significant tumor burden; and the lack of excessive CRS, NT, and other high-grade toxicities.
Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry
Samantha Jaglowski, et al.
In the real-world, tisa-cel has similar efficacy and improved safety in DLBCL patients. OOS product (viability 60-80%) does not impact efficacy
Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Children and Young Adults with Acute Lymphoblastic Leukemia (ALL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) Registry
Stephan Grupp, et al.
In the real-world, tisa-cel has similar efficacy and improved safety in pediatric ALL patients. OOS product (viability 60-80%) does not impact efficacy
Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England
Andrea Kuhnl, et al.
In this study, 122 patients were treated with axicabtagene ciloleucel and tisagenlecleucel. Details on bridging therapy, treatment-related toxicities and outcomes will be provided at the meeting, by which time 62 patients will have completed their 3 months PET response assessment
Real-World Analysis of Adverse Events Associated with CAR T-Cell Therapy Among Adults Age ≥65 Years
Marjorie E Zettler, et al.
This large-scale post-marketing report of CAR T-cell therapy associated AEs provides real-world evidence for use of CAR T-cell therapy in patients ≥65 and reports patterns of AEs observed based on age.